EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Reference values and primary sources Schematics, not to scale

Blood and lymph

How blood and lymph carry what the body absorbs: the two circuits, what blood is made of, the plasma proteins that bind and transport compounds, clotting and vitamin K, and the lymphatic route that lets fat-soluble compounds reach the blood without passing the liver first.

5.3 Lreference total blood volume of the adult man (3.9 L for the adult woman)
126 daysreference life span of a red blood cell in adults (range 112–154)
≈500×portal blood flow relative to intestinal lymph flow, which is why most absorbed molecules enter the blood
0.2%share of the adult body's lymphocytes that are in the blood at any one time

ICRP Publication 89 (2002), §7.2, §7.4 and §7.8.2; Trevaskis NL, Charman WN, Porter CJH. Adv Drug Deliv Rev 2008;60:702–716.

Status. Education, not medical advice. EUTECNIQ is in formation and has no laboratory, studies or clinical data. Figures restate published reference values and study results; schematics are drawn for this page and are not to scale.

Related: ADME, PK and PBPK · Bioavailability design · Dosage forms · Proteins and peptides

Circulation

Blood passes the lungs and the body in series, and the organs in parallel

The right ventricle pumps blood through the lungs to the left atrium; the left ventricle pumps it into the aorta and through every systemic capillary bed back to the right atrium. Blood from the gut, spleen and pancreas passes the liver before it rejoins the venous return. The adult reference cardiac output at rest is 6.5 L/min for men and 5.9 L/min for women.

One heart, two pumps: the right side feeds the lungs, the left side feeds every other organSchematic, not to scale
Double circulation: the right ventricle pumps blood through the lungs to the left atrium; the left ventricle pumps it through the systemic capillary beds back to the right atrium; lymph rejoins venous blood near the heartLungs: pulmonary capillariescarbon dioxide leaves the blood, oxygen entersHeart (drawn as seen from the front: the body's right is on the left)Right atriumLeft atriumRight ventricleLeft ventricletricuspid valvemitral valvepulmonary semilunar valve,pulmonary trunk and arteriespulmonary veinsPulmonary circuit: the whole cardiac output passes the lungsSystemic capillary beds in parallelbrain 12%, kidneys 19%, skeletal muscle 17%,skin 5%, adipose 5%, coronary 4% of cardiacoutputGut, spleen and pancreas → portal vein→ liverliver 25.5% of cardiac output in all: 6.5% bythe hepatic artery, the rest through the portalveinaortic semilunarvalve, aortavenous return: superior and inferior venae cavae to the right atriumlymphSystemic circuitoxygen-poor bloodoxygen-rich bloodlymph returning to veinsSchematic, not to scale · flows: ICRP 89 adult maleThe order in which blood passes the heart, lungs and body: right heart, pulmonary circuit, left heart, systemic circuit, and back to the right atriumOrder of passage (schematic)Right atriumreceives the superior and inferior venae cavaeand the coronary sinus1Tricuspid valve → right ventricle2Pulmonary semilunar valve → pulmonarytrunk and arteries3Lungs: pulmonary capillariescarbon dioxide leaves the blood, oxygen enters4Pulmonary veins → left atrium5Mitral valve → left ventricle6Aortic semilunar valve → aorta and arteries7Systemic capillary beds, in parallelgut, spleen and pancreas drain through the portalvein to the liver first8Veins → venae cavaelymph joins the venous blood near the heart9Steel: oxygen-poor blood · copper: oxygen-rich
Path and valves: OpenStax Anatomy and Physiology 2e, §19.1. Organ flows: ICRP Publication 89 (2002), §7.7.2, adult male, percent of cardiac output. Lymph return: OpenStax §21.1; Ilahi et al., StatPearls, Thoracic Duct (2023).
Text version of the drawing: the order of passage
  1. Right atriumReceives the superior and inferior venae cavae and the coronary sinus, which drains the heart muscle.
  2. Right ventricleFilled through the tricuspid valve; pumps oxygen-poor blood through the pulmonary semilunar valve into the pulmonary trunk and arteries.
  3. LungsIn the pulmonary capillaries carbon dioxide leaves the blood and oxygen enters.
  4. Left atrium and left ventricleThe pulmonary veins return blood to the left atrium; the mitral valve opens to the left ventricle, which pumps through the aortic semilunar valve into the aorta.
  5. Systemic capillary bedsOrgans are supplied in parallel: brain 12%, kidneys 19%, skeletal muscle 17%, skin 5%, adipose tissue 5%, coronary 4% of cardiac output (adult male). Gut, spleen and pancreas drain through the portal vein to the liver, which receives 25.5% of cardiac output in all, 6.5% of it by the hepatic artery.
  6. Venous returnVeins and the venae cavae return blood to the right atrium. Lymph enters the veins near the heart.
The kidneys hold 2% of the blood but receive 19% of the flow; skeletal muscle holds 14% and receives 17%ICRP Publication 89 reference values
Share of total blood volume and share of cardiac output for fourteen organs in the ICRP Publication 89 adult maleshare of total blood volume, %share of cardiac output, %0510152025LiverLiver: 10% of total blood volume10Liver: 25.5% of cardiac output25.5KidneysKidneys: 2% of total blood volume2Kidneys: 19% of cardiac output19Skeletal muscleSkeletal muscle: 14% of total blood volume14Skeletal muscle: 17% of cardiac output17BrainBrain: 1.2% of total blood volume1.2Brain: 12% of cardiac output12Small intestineSmall intestine: 3.8% of total blood volume3.8Small intestine: 10% of cardiac output10SkeletonSkeleton: 7% of total blood volume7Skeleton: 5% of cardiac output5Adipose tissueAdipose tissue: 5% of total blood volume5Adipose tissue: 5% of cardiac output5SkinSkin: 3% of total blood volume3Skin: 5% of cardiac output5Coronary tissueCoronary tissue: 1% of total blood volume1Coronary tissue: 4% of cardiac output4Large intestineLarge intestine: 2.2% of total blood volume2.2Large intestine: 4% of cardiac output4SpleenSpleen: 1.4% of total blood volume1.4Spleen: 3% of cardiac output3Bronchial tissueBronchial tissue: 2% of total blood volume2Bronchial tissue: 2.5% of cardiac output2.5Lymph nodesLymph nodes: 0.2% of total blood volume0.2Lymph nodes: 1.7% of cardiac output1.7ThyroidThyroid: 0.06% of total blood volume0.06Thyroid: 1.5% of cardiac output1.5Share of total blood volume and share of cardiac output for fourteen organs in the ICRP Publication 89 adult male% of blood volume% of cardiac output0510152025LiverLiver: 10% of total blood volume10Liver: 25.5% of cardiac output25.5KidneysKidneys: 2% of total blood volume2Kidneys: 19% of cardiac output19Skeletal muscleSkeletal muscle: 14% of total blood volume14Skeletal muscle: 17% of cardiac output17BrainBrain: 1.2% of total blood volume1.2Brain: 12% of cardiac output12Small intestineSmall intestine: 3.8% of total blood volume3.8Small intestine: 10% of cardiac output10SkeletonSkeleton: 7% of total blood volume7Skeleton: 5% of cardiac output5Adipose tissueAdipose tissue: 5% of total blood volume5Adipose tissue: 5% of cardiac output5SkinSkin: 3% of total blood volume3Skin: 5% of cardiac output5Coronary tissueCoronary tissue: 1% of total blood volume1Coronary tissue: 4% of cardiac output4Large intestineLarge intestine: 2.2% of total blood volume2.2Large intestine: 4% of cardiac output4SpleenSpleen: 1.4% of total blood volume1.4Spleen: 3% of cardiac output3Bronchial tissueBronchial tissue: 2% of total blood volume2Bronchial tissue: 2.5% of cardiac output2.5Lymph nodesLymph nodes: 0.2% of total blood volume0.2Lymph nodes: 1.7% of cardiac output1.7ThyroidThyroid: 0.06% of total blood volume0.06Thyroid: 1.5% of cardiac output1.5
ICRP Publication 89 (2002), §7.7.2, reference values for regional blood volumes and blood flow rates, adult male (adopted from Williams and Leggett 1989; Leggett and Williams 1991, 1995). Female values differ for adipose tissue (8.5% of volume and flow), skeletal muscle (10.5% and 12%) and some others.
Show data: blood content and blood flow by organ, adult male and female
Blood content as percent of total blood volume and blood flow as percent of cardiac output, ICRP reference adult male and female
Organ or tissueBlood content, % of total (male / female)Blood flow, % of cardiac output (male / female)
Liver10 / 1025.5 / 27.0 total (6.5 / 6.5 arterial)
Kidneys2.0 / 2.019 / 17
Skeletal muscle14 / 10.517 / 12
Brain1.2 / 1.212 / 12
Small intestine3.8 / 3.810 / 11
Skeleton (red marrow 4.0 / 4.0 of content, 3.0 / 3.0 of flow)7.0 / 7.05.0 / 5.0
Adipose tissue5.0 / 8.55.0 / 8.5
Skin3.0 / 3.05.0 / 5.0
Coronary tissue1.0 / 1.04.0 / 5.0
Large intestine2.2 / 2.24.0 / 5.0
Spleen1.4 / 1.43.0 / 3.0
Bronchial tissue2.0 / 2.02.5 / 2.5
Lymph nodes0.2 / 0.21.7 / 1.7
Thyroid0.06 / 0.061.5 / 1.5
Heart chambers (right + left)9.0 / 9.0—
Pulmonary circulation10.5 / 10.5— (all of the cardiac output)
Aorta and large arteries; large veins6.0; 18 (both sexes)—

ICRP Publication 89 (2002), §7.7.2. Rows not shown in the chart: stomach and esophagus 1.0 / 1.0 and 1.0 / 1.0; pancreas 0.6 and 1.0; adrenals 0.06 and 0.3; gonads; urinary bladder; all other tissues.

About 60% of the blood is in the systemic veins and only 5% in the systemic capillaries at any momentICRP Publication 89 reference values
Distribution of blood in the vascular system of the ICRP reference adult man: most of it is in the systemic veinsarteriescapillariesveinsheartHeart chambersHeart chambers: 9% of total blood volume9%Pulmonary arteriesPulmonary arteries: 3% of total blood volume3%Pulmonary capillariesPulmonary capillaries: 2% of total blood volume2%Pulmonary veinsPulmonary veins: 5.5% of total blood volume5.5%Aorta and large arteriesAorta and large arteries: 6% of total blood volume6%Small arteriesSmall arteries: 10% of total blood volume10%Systemic capillariesSystemic capillaries: 5% of total blood volume5%Small veinsSmall veins: 41.5% of total blood volume41.5%Large veinsLarge veins: 18% of total blood volume18%Percent of total blood volume, recumbent adult manDistribution of blood in the vascular system of the ICRP reference adult man: most of it is in the systemic veinsarteriescapillariesveinsheartHeart chambersHeart chambers: 9% of total blood volume9%Pulmonary arteriesPulmonary arteries: 3% of total blood volume3%Pulmonary capillariesPulmonary capillaries: 2% of total blood volume2%Pulmonary veinsPulmonary veins: 5.5% of total blood volume5.5%Aorta and large arteriesAorta and large arteries: 6% of total blood volume6%Small arteriesSmall arteries: 10% of total blood volume10%Systemic capillariesSystemic capillaries: 5% of total blood volume5%Small veinsSmall veins: 41.5% of total blood volume41.5%Large veinsLarge veins: 18% of total blood volume18%Percent of total blood volume, recumbent adult man
ICRP Publication 89 (2002), §7.6, distribution of blood in the vascular system of a recumbent adult man (from Brobeck 1979, Rothe 1983, Leggett and Williams 1991). Systemic veins: small veins 41.5% + large veins 18% = 59.5%, computed.
Show data: blood volume and cardiac output by age, and the vascular distribution
ICRP reference total blood volume and resting cardiac output by age and sex
AgeTotal blood volume, L (male / female)Cardiac output, L/min (male / female)
Newborn0.27 / 0.270.6 / 0.6
1 year0.5 / 0.51.2 / 1.2
5 years1.4 / 1.43.4 / 3.4
10 years2.4 / 2.45.0 / 5.0
15 years4.5 / 3.36.1 / 6.1
Adult5.3 / 3.96.5 / 5.9

ICRP Publication 89 (2002), §7.4 (18 studies of healthy subjects resting recumbent) and §7.5 (trimmed means of more than 50 studies). Vascular distribution, percent of total blood volume: heart chambers 9; pulmonary 10.5 (arteries 3, capillaries 2, veins 5.5); systemic 80.5 (aorta and large arteries 6, small arteries 10, capillaries 5, small veins 41.5, large veins 18).

Organ volumes and flows in physiologically based models come from tables like these; the model structure and the hepatic first pass are covered on ADME, PK and PBPK.

Composition

Red cells are about 43% of a man's blood and 38% of a woman's; plasma is the rest

Blood volume is essentially plasma plus red cells; white cells and platelets add little volume. Plasma is mostly water, with proteins making up nearly all of the rest. Reference values differ between sources and laboratories, so each number below names its source.

Of 5,300 mL of blood in the reference man, 2,300 mL is red cells; neutrophils and lymphocytes make up most white cellsICRP Publication 89 reference values
Reference volumes of red blood cells and plasma in adult men and women, and the typical percentage of each leukocyte type, from ICRP Publication 89A Blood volume, mL (adult reference values)MaleMale: red blood cells 2300 mLMale: plasma 3000 mL2,3003,000total 5,300FemaleFemale: red blood cells 1500 mLFemale: plasma 2400 mL1,5002,400total 3,900red blood cellsplasmaB Leukocytes, % of total (mean ± SD)Segmented neutrophilsSegmented neutrophils: 47% ± 9%47 ± 9LymphocytesLymphocytes: 35% ± 7%35 ± 7Juvenile neutrophilsJuvenile neutrophils: 8% ± 5%8 ± 5MonocytesMonocytes: 6.5% ± 2%6.5 ± 2EosinophilsEosinophils: 3% ± 2%3 ± 2BasophilsBasophils: 0.6% ± 0.5%0.6 ± 0.5Total leukocytes 7,000 (5,000–10,000) per mm³Reference volumes of red blood cells and plasma in adult men and women, and the typical percentage of each leukocyte type, from ICRP Publication 89A Blood volume, mL (adult reference values)MaleMale: red blood cells 2300 mLMale: plasma 3000 mL2,3003,000total 5,300FemaleFemale: red blood cells 1500 mLFemale: plasma 2400 mL1,5002,400total 3,900red blood cellsplasmaB Leukocytes, % of total (mean ± SD)Segmented neutrophilsSegmented neutrophils: 47% ± 9%47 ± 9LymphocytesLymphocytes: 35% ± 7%35 ± 7Juvenile neutrophilsJuvenile neutrophils: 8% ± 5%8 ± 5MonocytesMonocytes: 6.5% ± 2%6.5 ± 2EosinophilsEosinophils: 3% ± 2%3 ± 2BasophilsBasophils: 0.6% ± 0.5%0.6 ± 0.5Total leukocytes 7,000 (5,000–10,000) per mm³
ICRP Publication 89 (2002), §7.3 (red cell and plasma volumes, based on red cells at about 43% (42–52%) of blood volume in men and 38% (37–48%) in women) and §7.2.3 (typical leukocyte values summarized from ICRP Publication 23, 1975).
Reference values for blood and plasma from two sources, showing how values differ between sources
MeasureICRP Publication 89 (typical values)Other source
Red cells, share of blood volumeAbout 43% (42–52%) men; 38% (37–48%) womenAbout 47% men, 41% women; “about 45 percent” in normal blood (OpenStax §18.1)
Red cell count5.4 × 10⁶/mm³ adult male; 4.8 × 10⁶/mm³ adult femaleAbout 5.4 million/µL men; 4.8 million/µL women (OpenStax §18.3)
Hemoglobin, g/100 mL blood16.5 (male, 18–20 years); 14.5 (female, 18–20 years)—
Leukocytes7,000 (5,000–10,000)/mm³5,000 to 10,000/µL (OpenStax §18.4)
Platelets250,000 (140,000–440,000)/mm³150,000 to 450,000/µL, “although reference ranges may vary among laboratories” (StatPearls, Physiology, Platelet)
Plasma water94%About 92%; proteins about 7% of plasma volume; other solutes about 1% (OpenStax §18.1)
Blood pH7.4 (red cells 7.2)Average 7.4; 7.35 to 7.45 in a healthy person (OpenStax §18.1)
Plasma glucose95 mg/100 mL—
Specific gravityBlood 1.06; plasma 1.027; red cells 1.09—

ICRP Publication 89 (2002), §7.2–7.3. 1 mm³ = 1 µL. OpenStax Anatomy and Physiology 2e, §18.1, §18.3, §18.4; Denault D, Launico MV. Physiology, Platelet. StatPearls, updated September 14, 2026. A clinical laboratory reports its own reference intervals; these tables are for orientation only.

Show data: leukocyte types (ICRP Publication 89, §7.2.3)
Typical percentage of each leukocyte type in blood, mean and standard deviation
Leukocyte type% of leukocytes (mean ± SD)
Segmented neutrophils47 ± 9
Lymphocytes35 ± 7
Juvenile neutrophils8 ± 5
Monocytes6.5 ± 2
Eosinophils3 ± 2
Basophils0.6 ± 0.5

Life spans and production

Life spans of blood cells as stated by the named sources
CellLife span in the circulationSource
Red blood cell126 (112–154) days in adults; “up to 120 days”ICRP Publication 89, §7.2.2; OpenStax §18.3
Platelet7 to 10 days, then cleared by the spleen and liver; “about 10 days”StatPearls, Physiology, Platelet; OpenStax §18.4
Granular leukocytesHours to daysOpenStax §18.4
Memory B and T cellsMany yearsOpenStax §18.4

Adults produce about 3.5 × 10⁹ red cells per kilogram of body weight per day (men) and 2.63 × 10⁹ (women). For the 73 kg reference man that is about 2.6 × 10¹¹ per day, or about 3 million per second, consistent with the textbook figure of more than 2 million per second.

ICRP Publication 89 (2002), §7.2.2 and Table 2.9 (73 kg); OpenStax §18.3. Daily and per-second figures computed on this page.

Hematopoiesis

All blood cells come from hematopoietic stem cells. After birth most hematopoiesis occurs in red bone marrow; in adults it is largely restricted to the cranial and pelvic bones, the vertebrae, the sternum and the proximal ends of the femur and humerus. The reference adult man has 1,170 g of active marrow.

Myeloid progenitors give platelets, red cells, granulocytes and monocytes; lymphoid progenitors give B, T and NK cellsSchematic, classical model
Classical branching model of hematopoiesis: hematopoietic stem cells give rise, through multipotent progenitors, to common myeloid progenitors (platelets, erythrocytes, granulocytes, monocytes) and common lymphoid progenitors (B cells, T cells, natural killer cells)Hematopoietic stemcellred bone marrow inadultsself-renewalMultipotentprogenitorcannot self-renewCommon myeloidprogenitorCommon lymphoidprogenitorMegakaryocytePlateletsthrombopoietin (liver and kidneys)ProerythroblastErythrocyteserythropoietin (kidney)Myeloblast lineageNeutrophils, eosinophils,basophils and monocytesB-cell precursorB cells; plasma cells makeimmunoglobulinsdevelops in red marrowT-cell precursorT cellsmatures in the thymusNK lineageNatural killer cellsOther signals include colony-stimulating factors and interleukins.Schematic. Lineage-tracing studies now favor a more continuous model with fewer fixed branch points.Classical branching model of hematopoiesis: stem cells, multipotent progenitors, then myeloid and lymphoid lines and the mature cells each givesHematopoietic stem cellself-renews; in adults mainly in red bone marrowMultipotent progenitorcannot self-renewCommon myeloidprogenitorPlatelets (frommegakaryocytes;thrombopoietin) ·erythrocytes(erythropoietin) ·neutrophils, eosinophils,basophils and monocytes(myeloblast lineage)Common lymphoidprogenitorB cells, which becomeplasma cells that makeimmunoglobulins · T cells,which mature in thethymus · natural killercellsSchematic, classical model. Lineage tracing now favorsfewer fixed branch points.
Chapman J, Zhang Y. Histology, Hematopoiesis. StatPearls, updated May 1, 2023; OpenStax §18.2 (sites, thrombopoietin from liver and kidneys); Schoener B, Borger J. Erythropoietin Stimulating Agents. StatPearls, updated July 14, 2024 (erythropoietin from peritubular cells of the renal cortex, stimulates red cell production). Active marrow: ICRP Publication 89, Table 2.8.
Text version of the drawing

Hematopoietic stem cells self-renew or become multipotent progenitors, which cannot self-renew. These split into common myeloid progenitors, which give megakaryocytes (shedding platelets into marrow sinuses), erythrocytes (proerythroblast to reticulocyte, up to 5 days) and, through the myeloblast lineage, neutrophils, eosinophils, basophils and monocytes; and common lymphoid progenitors, which give B cells, T cells and natural killer cells. B cells develop in red marrow and plasma cells derived from them make immunoglobulins; T cells mature in the thymus. Signals include erythropoietin, thrombopoietin, colony-stimulating factors and interleukins. Lineage-tracing studies have revised this branching picture toward a more continuous one.

Plasma proteins

The liver makes most plasma proteins; plasma cells make the immunoglobulins

Albumin is about 54% of plasma protein, globulins about 38% and fibrinogen about 7%. Many of these proteins are carriers: they hold hormones, vitamins, metals and drugs in the blood and release them in equilibrium. Several change during inflammation, which changes how much of a bound compound is free.

Plasma proteins: where they are made, what they do, what they bind, and their direction as acute-phase proteins
Protein (gene)Made mainly inFunctionBinds or carriesIn inflammation
Albumin (ALB)Liver hepatocytes, 10–15 g/dayMain regulator of colloid osmotic pressureWater, Ca²⁺, Na⁺, K⁺, fatty acids (up to 9), hormones, bilirubin, drugs; about 80% of plasma zinc; drugs at Sudlow site I (warfarin) and site II (diazepam, ibuprofen)Falls (negative)
Alpha-1-acid glycoprotein (ORM1)LiverTransport protein; modulates immune activity in the acute phaseLigands inside its β-barrel; synthetic drugs; basic drugs bind predominantly to itRises (positive)
Transferrin (TF)LiverCarries iron from absorption and heme breakdown to storage and useTwo Fe³⁺ ions, each with an anion, usually bicarbonateFalls (negative)
Ferritin (FTL, FTH1)Liver (heavy chain)Stores iron in a soluble, non-toxic, readily available formIron, deposited as ferric hydroxidesRises (positive)
Ceruloplasmin (CP)LiverFerroxidase: oxidizes Fe²⁺ to Fe³⁺ for loading onto transferrin6–7 copper atoms per moleculeListed among acute-phase proteins; direction not stated
Haptoglobin (HP)LiverCaptures free hemoglobin so the liver recycles heme iron and the kidney is protectedHemoglobinRises (positive); falls in hemolysis
Sex hormone–binding globulin (SHBG)Liver; testisAndrogen transport; regulates the plasma clearance rate of steroid hormonesDihydrotestosterone, testosterone, 17β-estradiol; one steroid per dimer—
Thyroxine-binding globulin (SERPINA7)LiverMajor thyroid hormone transport protein in serumThyroid hormones—
Transthyretin (TTR)Choroid plexus; also liver and retinal pigment epitheliumThyroid hormone binding; probably carries thyroxine from blood to brainThyroxineFalls (negative)
Vitamin D–binding protein (GC)LiverVitamin D transport and storage; scavenges extracellular G-actinVitamin D—
Retinol-binding protein 4 (RBP4)LiverDelivers retinol from liver stores to tissues, handing it to the STRA6 receptorAll-trans retinolFalls (negative)
Immunoglobulins (IGHG1 and others)Plasma cells, derived from B cellsAntibodies; about 20% of plasma proteinSpecific antigens—
Complement C3 (C3)LiverCleaved to C3b, which coats pathogens for removal, and C3a, a local inflammatory mediatorC3b binds covalently to pathogen surfaces—
Fibrinogen (FGA, FGB, FGG)LiverConverted by thrombin to fibrin, the main structural part of a clot; 200–400 mg/dL; half-life 3–4 days—Rises (positive)

Function, ligands and tissue: UniProt entries P02768, P02763, P02787, P02792, P02794, P00450, P00738, P04278, P05543, P02766, P02774, P02753, P01857, P01024, P02671 (retrieved October 30, 2026). Albumin synthesis, Sudlow sites and fatty acids: Moman RN, et al. Physiology, Albumin. StatPearls, updated January 31, 2026. Basic drugs and alpha-1-acid glycoprotein: Bisht S, et al. StatPearls, updated March 22, 2026. Acute-phase direction: Gulhar R, et al. Physiology, Acute Phase Reactants. StatPearls, 2023. Immunoglobulins: Patel P, et al. StatPearls, 2023; fibrinogen: Kaur J, et al. StatPearls, 2025. Plasma protein fractions: OpenStax §18.1.

Twenty of 22 plasma-protein genes are expressed most in the liver; transthyretin peaks in the choroid plexusHuman Protein Atlas data
RNA level of 22 plasma-protein genes in the tissue where the Human Protein Atlas finds them highest: liver for 20 of them, choroid plexus for transthyretin and lymphoid tissue for an immunoglobulin heavy chainliverother tissue (named)101001,00010,000100,00010⁶nTPM in that tissue (log scale)Transthyretin (TTR): choroid plexusTTR, Transthyretin: 672,504.5 nTPM in choroid plexus; HPA category Tissue enriched672,504Albumin (ALB)ALB, Albumin: 198,523.8 nTPM in liver; HPA category Tissue enriched198,524Haptoglobin (HP)HP, Haptoglobin: 55,848.1 nTPM in liver; HPA category Tissue enriched55,848Alpha-1-acid glycoprotein 1 (ORM1)ORM1, Alpha-1-acid glycoprotein 1: 42,168.4 nTPM in liver; HPA category Tissue enriched42,168Apolipoprotein A-I (APOA1)APOA1, Apolipoprotein A-I: 20,151.0 nTPM in liver; HPA category Tissue enriched20,151Fibrinogen alpha chain (FGA)FGA, Fibrinogen alpha chain: 17,201.5 nTPM in liver; HPA category Tissue enriched17,202Ferritin light chain (FTL)FTL, Ferritin light chain: 14,257.7 nTPM in liver; HPA category Tissue enhanced14,258Retinol-binding protein 4 (RBP4)RBP4, Retinol-binding protein 4: 11,054.0 nTPM in liver; HPA category Tissue enriched11,054IgG1 heavy chain constant region (IGHG1): lymphoid tissueIGHG1, IgG1 heavy chain constant region: 10,950.9 nTPM in lymphoid tissue; HPA category Group enriched10,951Vitamin D-binding protein (GC)GC, Vitamin D-binding protein: 7,722.0 nTPM in liver; HPA category Tissue enriched7,722Transferrin (TF)TF, Transferrin: 7,020.0 nTPM in liver; HPA category Group enriched7,020Complement C3 (C3)C3, Complement C3: 5,062.4 nTPM in liver; HPA category Tissue enriched5,062Ceruloplasmin (CP)CP, Ceruloplasmin: 1,750.2 nTPM in liver; HPA category Tissue enriched1,750Prothrombin (F2)F2, Prothrombin: 1,138.4 nTPM in liver; HPA category Tissue enriched1,138Apolipoprotein B (APOB)APOB, Apolipoprotein B: 1,114.1 nTPM in liver; HPA category Group enriched1,114Factor IX (F9)F9, Factor IX: 659.1 nTPM in liver; HPA category Tissue enriched659Protein C (PROC)PROC, Protein C: 584.1 nTPM in liver; HPA category Tissue enriched584Protein S (PROS1)PROS1, Protein S: 264.9 nTPM in liver; HPA category Tissue enhanced265Thyroxine-binding globulin (SERPINA7)SERPINA7, Thyroxine-binding globulin: 263.9 nTPM in liver; HPA category Tissue enriched264Factor X (F10)F10, Factor X: 149.7 nTPM in liver; HPA category Tissue enhanced150Factor VII (F7)F7, Factor VII: 128.6 nTPM in liver; HPA category Tissue enriched129Sex hormone-binding globulin (SHBG)SHBG, Sex hormone-binding globulin: 59.3 nTPM in liver; HPA category Tissue enriched59RNA level of 22 plasma-protein genes in the tissue where the Human Protein Atlas finds them highest: liver for 20 of them, choroid plexus for transthyretin and lymphoid tissue for an immunoglobulin heavy chainliverother tissue (named)101001,00010,000100,00010⁶nTPM in that tissue (log scale)Transthyretin (TTR), choroid plexusTTR, Transthyretin: 672,504.5 nTPM in choroid plexus; HPA category Tissue enriched672,504Albumin (ALB)ALB, Albumin: 198,523.8 nTPM in liver; HPA category Tissue enriched198,524Haptoglobin (HP)HP, Haptoglobin: 55,848.1 nTPM in liver; HPA category Tissue enriched55,848Alpha-1-acid glycoprotein 1 (ORM1)ORM1, Alpha-1-acid glycoprotein 1: 42,168.4 nTPM in liver; HPA category Tissue enriched42,168Apolipoprotein A-I (APOA1)APOA1, Apolipoprotein A-I: 20,151.0 nTPM in liver; HPA category Tissue enriched20,151Fibrinogen alpha chain (FGA)FGA, Fibrinogen alpha chain: 17,201.5 nTPM in liver; HPA category Tissue enriched17,202Ferritin light chain (FTL)FTL, Ferritin light chain: 14,257.7 nTPM in liver; HPA category Tissue enhanced14,258Retinol-binding protein 4 (RBP4)RBP4, Retinol-binding protein 4: 11,054.0 nTPM in liver; HPA category Tissue enriched11,054IgG1 heavy chain constant region (IGHG1), lymphoid tissueIGHG1, IgG1 heavy chain constant region: 10,950.9 nTPM in lymphoid tissue; HPA category Group enriched10,951Vitamin D-binding protein (GC)GC, Vitamin D-binding protein: 7,722.0 nTPM in liver; HPA category Tissue enriched7,722Transferrin (TF)TF, Transferrin: 7,020.0 nTPM in liver; HPA category Group enriched7,020Complement C3 (C3)C3, Complement C3: 5,062.4 nTPM in liver; HPA category Tissue enriched5,062Ceruloplasmin (CP)CP, Ceruloplasmin: 1,750.2 nTPM in liver; HPA category Tissue enriched1,750Prothrombin (F2)F2, Prothrombin: 1,138.4 nTPM in liver; HPA category Tissue enriched1,138Apolipoprotein B (APOB)APOB, Apolipoprotein B: 1,114.1 nTPM in liver; HPA category Group enriched1,114Factor IX (F9)F9, Factor IX: 659.1 nTPM in liver; HPA category Tissue enriched659Protein C (PROC)PROC, Protein C: 584.1 nTPM in liver; HPA category Tissue enriched584Protein S (PROS1)PROS1, Protein S: 264.9 nTPM in liver; HPA category Tissue enhanced265Thyroxine-binding globulin (SERPINA7)SERPINA7, Thyroxine-binding globulin: 263.9 nTPM in liver; HPA category Tissue enriched264Factor X (F10)F10, Factor X: 149.7 nTPM in liver; HPA category Tissue enhanced150Factor VII (F7)F7, Factor VII: 128.6 nTPM in liver; HPA category Tissue enriched129Sex hormone-binding globulin (SHBG)SHBG, Sex hormone-binding globulin: 59.3 nTPM in liver; HPA category Tissue enriched59
Human Protein Atlas, consensus RNA tissue data (nTPM) and tissue specificity categories, gene pages retrieved October 30, 2026. “Tissue enriched”: at least four-fold higher mRNA level in one tissue than in any other. mRNA level indicates where a protein is made; it is not a plasma concentration.
Show data: HPA tissue of highest expression, nTPM and specificity category
Human Protein Atlas RNA tissue specificity for 22 plasma-protein genes
Gene (protein)TissuenTPMHPA category
TTR (transthyretin)Choroid plexus672,504.5Tissue enriched
ALB (albumin)Liver198,523.8Tissue enriched
HP (haptoglobin)Liver55,848.1Tissue enriched
ORM1 (alpha-1-acid glycoprotein 1)Liver42,168.4Tissue enriched
APOA1 (apolipoprotein A-I)Liver20,151.0Tissue enriched
FGA (fibrinogen alpha chain)Liver17,201.5Tissue enriched
FTL (ferritin light chain)Liver14,257.7Tissue enhanced
RBP4 (retinol-binding protein 4)Liver11,054.0Tissue enriched
IGHG1 (IgG1 heavy chain constant region)Lymphoid tissue (also urinary bladder 3,756.3)10,950.9Group enriched
GC (vitamin D–binding protein)Liver7,722.0Tissue enriched
TF (transferrin)Liver (also retina 2,256.7)7,020.0Group enriched
C3 (complement C3)Liver5,062.4Tissue enriched
CP (ceruloplasmin)Liver1,750.2Tissue enriched
F2 (prothrombin)Liver1,138.4Tissue enriched
APOB (apolipoprotein B)Liver (also intestine 286.7)1,114.1Group enriched
F9 (factor IX)Liver659.1Tissue enriched
PROC (protein C)Liver584.1Tissue enriched
PROS1 (protein S)Liver (also choroid plexus 133.4)264.9Tissue enhanced
SERPINA7 (thyroxine-binding globulin)Liver263.9Tissue enriched
F10 (factor X)Liver149.7Tissue enhanced
F7 (factor VII)Liver128.6Tissue enriched
SHBG (sex hormone–binding globulin)Liver59.3Tissue enriched

Lipoproteins carry fat and fat-soluble compounds

Lipoprotein classes: origin, apolipoproteins, cargo and size where a source states it
ClassOriginApolipoproteinsCargo and properties
ChylomicronEnterocytes of the small intestine, from dietary lipidB-48 (one per particle), A-I, A-II, A-IV, C-I, C-II, C-III, EMore than 75% triglyceride, about 2% protein; density below 0.94 g/mL; 75–1,200 nm
VLDLLiver; MTP is required for its lipidationB-100, C-I, C-II, C-III, EEndogenous triglyceride and some cholesterol; 30–80 nm
IDLRemnant of VLDL after lipoprotein lipase actsB-100, C-III, ECholesterol esters and triglyceride
LDLFormed from IDL through hepatic lipaseB-100, one per particle, the ligand for the LDL receptorCholesterol esters
HDLApolipoprotein A-I is made in liver and small intestineA-I, A-II, C-I, C-II, C-III, D, ECholesterol esters; apoA-I promotes cholesterol efflux from tissues to the liver

Lent-Schochet D, Jialal I. Biochemistry, Lipoprotein Metabolism. StatPearls, 2023; Rahmany S, Jialal I. Biochemistry, Chylomicron. StatPearls, 2023; Devaraj S, et al. Biochemistry, Apolipoprotein B. StatPearls, 2023; UniProt P02647 (APOA1), P04114 (APOB). Sizes: Yáñez JA, et al. Adv Drug Deliv Rev 2011;63:923–942. ApoB-48 is formed in the intestine by apoB mRNA editing (APOBEC1).

Protein binding and the unbound fraction

In plasma a compound is in equilibrium between bound and unbound forms. The unbound fraction fu = Cunbound/Ctotal is the part that is pharmacologically active and subject to tissue distribution and elimination. Acidic compounds bind mainly to albumin and basic ones mainly to alpha-1-acid glycoprotein; lipoproteins are a third class of binding protein.

Lower albumin leaves fewer binding sites and raises the unbound fraction of highly albumin-bound drugs. Displacement from a binding site raises the free fraction only transiently, because the extra unbound drug is also cleared faster; warfarin displaced by sulfonamides or NSAIDs is the textbook example. How fu enters hepatic extraction and PBPK models is shown on ADME, PK and PBPK.

Bisht S, Chauhan V, Patel P. Clinical Significance of Volume of Distribution in Pharmacotherapy. StatPearls, updated March 22, 2026; Moman RN, et al. Physiology, Albumin. StatPearls, 2026 (unbound drug “pharmacologically active and subject to tissue distribution and elimination”).

Coagulation

Factors II, VII, IX and X and proteins C and S need vitamin K to be completed, and warfarin blocks its recycling

Hemostasis begins with vessel spasm and a platelet plug; coagulation then builds a fibrin mesh that stabilizes the plug. The clotting factors circulate as inactive zymogens and activate each other in sequence. The liver makes most of them, and it needs vitamin K to finish factors II, VII, IX and X and the regulators protein C and protein S. Protein Z, the cofactor that lets protein Z–dependent protease inhibitor inactivate factor Xa, is also vitamin K–dependent.

Both pathways converge on factor X; thrombin then turns fibrinogen into fibrinSchematic
Coagulation cascade: the intrinsic pathway (XII, XI, IX with VIII) and the extrinsic pathway (tissue factor with VII) both activate factor X; Xa with Va converts prothrombin to thrombin, which converts fibrinogen to fibrin, cross-linked by XIIIa. Factors II, VII, IX, X and proteins C and S are vitamin K-dependentIntrinsic pathway (measured by PTT)Extrinsic pathway (measured by PT)XII → XIIaon exposure to collagen after endothelialdamageXI → XIaIX → IXawith cofactor VIIIa, Ca²⁺ and phospholipid(intrinsic tenase)Tissue factor (factor III)released after vascular injuryVII → VIIatissue factor–VIIa with Ca²⁺ (extrinsictenase)X → Xaboth pathways converge hereProthrombin (II) → thrombin (IIa)Xa with cofactor Va, Ca²⁺ and phospholipid(prothrombinase)Fibrinogen (I) → fibrinthrombin cleaves fibrinogen; fibrin strands formXIIIa cross-links fibrina fibrin mesh stabilizes the platelet plugKKKKFeedback: thrombin also activates XI andcofactors V, VIII and XIIINatural brakesActivated protein C, with protein Sinactivates Va and VIIIaKAntithrombinopposes thrombin formation; inactivates XaTissue factor pathway inhibitorinhibits the extrinsic pathwayPlasminbreaks down fibrinKvitamin K–dependent: γ-carboxylated(Gla) protein; II, VII, IX, X, C, SSchematic; the cell-surface reactions are drawn as a sequenceCoagulation cascade in sequence: intrinsic and extrinsic pathways converge on factor X; thrombin then makes fibrin; vitamin K-dependent factors are marked KIntrinsic (PTT)Extrinsic (PT)XII → XIIacollagen exposed bydamageXI → XIaIX → IXawith VIIIa, Ca²⁺,phospholipidTissue factor (III)released after injuryVII → VIIawith tissue factor, Ca²⁺KKX → Xaboth pathways convergeKProthrombin (II) → thrombin (IIa)Xa with Va, Ca²⁺, phospholipidKFibrinogen (I) → fibrinXIIIa cross-links fibrinstabilizes the platelet plugNatural brakesActivated protein C with protein S (both K)inactivate Va and VIIIaAntithrombinopposes thrombin formation; inactivates XaTissue factor pathway inhibitorinhibits the extrinsic pathwayPlasminbreaks down fibrinKvitamin K–dependent (Gla) protein: II, VII, IX, X, C, S
Chaudhry R, Killeen RB, Babiker HM. Physiology, Coagulation Pathways. StatPearls, updated June 2, 2025 (pathways; protein Z); OpenStax §18.5 (tissue factor pathway inhibitor, antithrombin, protein C, plasmin); UniProt P00734, P08709, P00740, P00742, P04070, P07225. Vitamin K–dependent factors: Patel S, et al. Warfarin. StatPearls, updated October 5, 2024.
Text version of the drawing

Intrinsic pathway: factor XII is activated on exposure to collagen after endothelial damage; XIIa activates XI, XIa activates IX, and IXa with cofactor VIIIa, Ca²⁺ and phospholipid (intrinsic tenase) activates X. Extrinsic pathway: tissue factor (factor III) released after vascular injury forms a complex with VIIa and Ca²⁺ (extrinsic tenase) that activates X. Common pathway: Xa with cofactor Va, Ca²⁺ and phospholipid (prothrombinase) converts prothrombin (II) to thrombin (IIa); thrombin converts fibrinogen (I) to fibrin, and XIIIa cross-links the fibrin into a mesh. Thrombin also activates factor XI, the cofactors V and VIII, and factor XIII. Brakes: activated protein C with protein S inactivates Va and VIIIa; antithrombin opposes thrombin formation and inactivates Xa; tissue factor pathway inhibitor inhibits the extrinsic pathway; plasmin breaks down fibrin. The partial thromboplastin time (PTT) assesses the intrinsic pathway and the prothrombin time (PT) the extrinsic pathway.

Each carboxylation consumes reduced vitamin K; VKORC1 regenerates it, and that is the step warfarin inhibitsSchematic
Vitamin K cycle: vitamin K is reduced to the hydroquinone; gamma-glutamyl carboxylase uses it to convert glutamate to gamma-carboxyglutamate on clotting factor precursors and forms vitamin K epoxide; VKORC1 reduces the epoxide back; warfarin inhibits VKORC1Vitamin K (quinone)from diet or recyclingVitamin K hydroquinone (KH₂)the reduced, active formVitamin K 2,3-epoxideformed as Glu is carboxylatedreduction (VKOR)GGCX, EC 4.1.1.90Glu → Gla on precursor proteinsfactors II, VII, IX, X, proteins C and S, osteocalcin,matrix Gla protein; Gla binds Ca²⁺VKORC1 (EC 1.17.4.4) reduces the epoxide back to vitamin Kwarfarin inhibits VKORC1Vitamin K cycle: vitamin K is reduced to the hydroquinone; gamma-glutamyl carboxylase uses it to convert glutamate to gamma-carboxyglutamate on clotting factor precursors and forms vitamin K epoxide; VKORC1 reduces the epoxide back; warfarin inhibits VKORC1Vitamin K (quinone)Vitamin K hydroquinone (KH₂)reduction (VKOR)GGCX (EC 4.1.1.90): Glu → Glaon II, VII, IX, X, C, S, osteocalcin, matrix Gla proteinVitamin K 2,3-epoxideVKORC1 (EC 1.17.4.4) returns the epoxide to vitamin K(left arrow).Warfarin inhibits VKORC1.
UniProt P38435 (GGCX, vitamin K-dependent gamma-carboxylase, EC 4.1.1.90) and Q9BQB6 (VKORC1, EC 1.17.4.4), retrieved October 30, 2026; Imbrescia K, Moszczynski Z. Vitamin K. StatPearls, updated July 10, 2023; Patel S, et al. Warfarin. StatPearls, 2024.
Text version of the drawing

Vitamin K is reduced to vitamin K hydroquinone by VKORC1; a warfarin-resistant second reductase, FSP1, was identified in 2022 (Mishima E, et al. Nature 2022;608:778–783, doi:10.1038/s41586-022-05022-3). Gamma-glutamyl carboxylase (GGCX) uses the hydroquinone to convert glutamate (Glu) residues of precursor proteins to gamma-carboxyglutamate (Gla), which binds calcium, and in the same active site forms vitamin K 2,3-epoxide. VKORC1 reduces the epoxide back to vitamin K. GGCX substrates include factors II, VII, IX and X, protein C, osteocalcin and matrix Gla protein. Warfarin competitively inhibits VKORC1, so the liver releases clotting factors that lack enough Gla residues.

Platelets

Platelets are 3–4 µm anucleate fragments of bone marrow megakaryocytes; thrombopoietin is their main growth factor. At an injury they adhere to exposed collagen, held by von Willebrand factor, then activate and aggregate into the primary plug that fibrin later stabilizes.

Denault D, Launico MV. Physiology, Platelet. StatPearls, updated September 14, 2026; OpenStax §18.5.

Supplements and anticoagulants

In crossover studies, St John's wort lowered warfarin's effect; ginkgo and ginger did not change it

Warfarin is 99% protein bound and is metabolized mainly by CYP2C9. A supplement can change its effect by supplying vitamin K or by changing its clearance. The human studies below measured both the drug and its effect, the international normalized ratio (INR) of prothrombin time.

St John's wort raised warfarin clearance by about a quarter and lowered INR exposure by about a fifthHuman pharmacokinetic studies
Ratios, with 90% confidence intervals, of warfarin apparent clearance and of the INR area under the curve with and without St John's wort, ginkgo or ginger, in two crossover studies of 12 healthy menA Apparent clearance of warfarin, ratio with/without herb0.60.81.01.21.41.6St John's wort, S-warfarinSt John's wort, S-warfarin: 1.29 (90% CI 1.16–1.46)1.29St John's wort, R-warfarinSt John's wort, R-warfarin: 1.23 (90% CI 1.11–1.37)1.23Ginkgo, S-warfarinGinkgo, S-warfarin: 1.05 (90% CI 0.98–1.21)1.05Ginkgo, R-warfarinGinkgo, R-warfarin: 1.00 (90% CI 0.93–1.08)1.00Ginger, S-warfarinGinger, S-warfarin: 1.05 (90% CI 0.97–1.13)1.05Ginger, R-warfarinGinger, R-warfarin: 1.02 (90% CI 0.95–1.10)1.02B INR AUC₀–₁₆₈ h, ratio with/without herb0.60.81.01.21.41.6St John's wortSt John's wort: 0.79 (90% CI 0.70–0.95)0.79GinkgoGinkgo: 0.93 (90% CI 0.81–1.05)0.93GingerGinger: 1.01 (90% CI 0.93–1.15)1.01Ratio (90% CI). Rose: interval excludes 1 (no change). Dashed line: ratio 1.Ratios, with 90% confidence intervals, of warfarin apparent clearance and of the INR area under the curve with and without St John's wort, ginkgo or ginger, in two crossover studies of 12 healthy menA Apparent clearance of warfarin, ratioSt John's wort, S-warfarinSt John's wort, S-warfarin: 1.29 (90% CI 1.16–1.46)1.29St John's wort, R-warfarinSt John's wort, R-warfarin: 1.23 (90% CI 1.11–1.37)1.23Ginkgo, S-warfarinGinkgo, S-warfarin: 1.05 (90% CI 0.98–1.21)1.05Ginkgo, R-warfarinGinkgo, R-warfarin: 1.00 (90% CI 0.93–1.08)1.00Ginger, S-warfarinGinger, S-warfarin: 1.05 (90% CI 0.97–1.13)1.05Ginger, R-warfarinGinger, R-warfarin: 1.02 (90% CI 0.95–1.10)1.020.61.01.4B INR AUC₀–₁₆₈ h, ratioSt John's wortSt John's wort: 0.79 (90% CI 0.70–0.95)0.79GinkgoGinkgo: 0.93 (90% CI 0.81–1.05)0.93GingerGinger: 1.01 (90% CI 0.93–1.15)1.010.61.01.4Rose: interval excludes 1. Dashed line: no change.
Jiang X, et al. Br J Clin Pharmacol 2004;57:592–599 (St John's wort, 14 days' pretreatment) and 2005;59:425–432 (ginkgo, ginger, 7 days); open-label, randomized three-way crossover studies in 12 healthy men given a single 25 mg dose of warfarin. Mean ratio with 90% confidence interval.
Show data: ratios with and without each herbal product
Warfarin clearance and INR ratios with St John's wort, ginkgo and ginger
Herbal productS-warfarin apparent clearance, ratio (90% CI)R-warfarin apparent clearance, ratio (90% CI)INR AUC0–168 h, ratio (90% CI)
St John's wort1.29 (1.16–1.46)1.23 (1.11–1.37)0.79 (0.70–0.95)
Ginkgo1.05 (0.98–1.21)1.00 (0.93–1.08)0.93 (0.81–1.05)
Ginger1.05 (0.97–1.13)1.02 (0.95–1.10)1.01 (0.93–1.15)

Jiang et al. 2004 and 2005, abstracts. None of the four products changed the protein binding or apparent volume of distribution of either warfarin enantiomer, or platelet aggregation.

Documented interactions between supplements and warfarin, with the evidence type
SupplementWhat was documentedEvidence
Vitamin KWarfarin and similar anticoagulants antagonize vitamin K; people taking them “need to maintain a consistent intake of vitamin K from food and supplements because sudden changes in vitamin K intakes can increase or decrease the anticoagulant effect”NIH Office of Dietary Supplements fact sheet, updated October 22, 2026
St John's wortInduced S- and R-warfarin clearance and reduced the effect of rac-warfarinCrossover study, 12 healthy men (Jiang 2004)
American ginsengPeak INR fell after 2 weeks compared with placebo (difference −0.19; 95% CI −0.36 to −0.07); warfarin AUC and peak level also fellRandomized, double-blind, placebo-controlled trial, 20 healthy adults (Yuan 2004)
Ginseng (product in Jiang 2004)No change in warfarin pharmacokinetics or pharmacodynamicsCrossover study, 12 healthy men
Ginkgo, gingerNo significant effect on clotting status, warfarin pharmacokinetics or INR; platelet aggregation unchangedCrossover study, 12 healthy men (Jiang 2005)
Green teaAssociated with inhibiting warfarin's effect and lowering INR, attributed to its vitamin K contentClinical review (StatPearls, Warfarin Drug Interactions)

NIH ODS, Vitamin K, Fact Sheet for Health Professionals; Jiang X, et al. 2004 and 2005; Yuan CS, et al. Ann Intern Med 2004;141:23–27; Crader MF, Johns T, Arnold JK. Warfarin Drug Interactions. StatPearls, 2023 (herbal products are poorly standardized, which makes interactions hard to demonstrate); Patel S, et al. Warfarin. StatPearls, 2024 (99% protein bound; CYP2C9). Single-dose studies in healthy volunteers do not reproduce long-term therapy in patients.

Lymphatic system

Lymph returns filtered fluid and protein to the veins through one-way vessels and the thoracic duct

Capillaries filter plasma into the tissues and reabsorb most of it. The rest, with protein that leaked out, enters blind-ended lymphatic capillaries and becomes lymph. Collecting vessels with valves carry it through lymph nodes to the thoracic duct and the right lymphatic duct, which empty into the great veins of the neck.

Of 20 liters filtered from capillaries each day, 17 are reabsorbed and 3 return as lymphSchematic, not to scale
Lymph formation and route: about 20 liters of plasma filter into the tissues each day, about 17 are reabsorbed and about 3 enter lymphatic capillaries; lymph passes collecting vessels, nodes and trunks to the thoracic duct, which empties at the left venous angleBlood capillaryInterstitial fluidfiltered20 L/dayreabsorbed17 L/day3 L/day enters lymphLymphatic capillary: flaps open when outside pressure ishigher1Lymphatic capillariesblind-ended; overlapping endothelial cells form button-like openings;anchoring filaments; no valves2Collecting lymphatic vesselsone-way valves; contractile cells pump lymph3Lymph nodesfilter lymph; at least 600–700 in the body (ICRP 89)4Trunks and cisterna chylia lymph sac at L2 where the lumbar and intestinal trunks converge; theintestinal trunk brings chyle5Thoracic duct38–45 cm long, 2–5 mm wide; drains most of the body6Venous anglejunction of the left internal jugular and subclavian veins1Right lymphatic duct: the upper right body drains to the right venousangle instead.Lymph formation and route: about 20 liters of plasma filter into the tissues each day, about 17 are reabsorbed and about 3 enter lymphatic capillaries; lymph passes collecting vessels, nodes and trunks to the thoracic duct, which empties at the left venous angleBlood capillaryInterstitial fluidfiltered20 L/dayreabsorbed17 L/day3 L/day enters lymphLymphatic capillary: flaps open when outsidepressure is higher11Lymphatic capillariesblind-ended; overlapping endothelial cells formbutton-like openings; anchoring filaments; novalves2Collecting lymphatic vesselsone-way valves; contractile cells pump lymph3Lymph nodesfilter lymph; at least 600–700 in the body (ICRP 89)4Trunks and cisterna chylia lymph sac at L2 where the lumbar and intestinaltrunks converge; the intestinal trunk brings chyle5Thoracic duct38–45 cm long, 2–5 mm wide; drains most of thebody6Venous anglejunction of the left internal jugular and subclavianveinsRight lymphatic duct: the upper right body drains to theright venous angle.
Volumes: OpenStax §21.1. Capillary structure, valves and pumping: Ozdowski L, Gupta V. Physiology, Lymphatic System. StatPearls, 2023; Null M, et al. Anatomy, Lymphatic System. StatPearls, 2023. Nodes: ICRP Publication 89, §7.8.1. Thoracic duct and cisterna chyli: Ilahi M, et al. StatPearls, 2023; Null M, et al. StatPearls, 2023.
Text version of the drawing
  1. Lymphatic capillariesA single layer of partially overlapping endothelial cells forms button-like openings that let fluid in when the pressure outside is higher; collagen filaments anchor them; they have no valves.
  2. Collecting vesselsOne-way valves prevent backflow; contractile cells pump lymph. At rest this intrinsic pump drives two-thirds of lymph flow; skeletal muscle compression drives the rest.
  3. Lymph nodesFilter lymph; dendritic cells and macrophages inside them trap and destroy many pathogens.
  4. Trunks and cisterna chyliThe thoracic duct runs from the cisterna chyli, a lymph sac at L2 where the lumbar and intestinal lymphatic trunks converge; the intestinal trunk brings chyle. The sac is present in about 40–60% of people; without it the trunks join the duct directly.
  5. Thoracic duct38–45 cm long and 2–5 mm in diameter; drains most of the body except the right upper thorax, the right side of the head and neck and the right arm.
  6. Venous angleIn over 95% of people the duct ends in the internal jugular vein, the subclavian vein or the angle between them; it ends on the right in 2–3%.
Published estimates of lymph flow and lymph node number, which differ between sources
QuantityValue as statedSource
Lymph formed per day3 L (20 L filtered, 17 L reabsorbed)OpenStax §21.1
Lymphatic fluid and protein transported per day8 to 12 LStatPearls, Physiology, Lymphatic System
Thoracic duct output1.38 mL/kg/hour (about 2.4 L/day for a 73 kg adult, computed)StatPearls, Thoracic Duct
Number of lymph nodesAt least 600–700; 200–500 in the mesenteryICRP Publication 89, §7.8.1
Number of lymph nodesApproximately 450StatPearls, Physiology, Lymphatic System

The sources do not explain the spread; read these as orders of magnitude. OpenStax gives the left subclavian vein as the thoracic duct's end; StatPearls describes the junction of the subclavian and internal jugular veins and its variants.

Intestinal lymph

Highly lipophilic compounds can travel in chylomicrons through the lymph and skip the liver's first pass

Each intestinal villus usually has one central lymphatic vessel, the lacteal. Portal blood brings the liver everything absorbed from the gut except most of the lipid, which travels in the mesenteric lymph to the thoracic duct. A compound that rides in chylomicrons follows the same path and reaches the systemic veins without first meeting the liver.

Chylomicrons are too large for blood capillaries, so they and the lipophilic compounds they carry leave through the lactealSchematic, not to scale
Lipid uptake by an intestinal villus: digestion products and dissolved lipophilic compounds enter the enterocyte, are packed into chylomicrons on apoB-48 and leave into the lacteal, while most other absorbed molecules enter the blood capillary and the portal veinIntestinal lumenLamina propriaBlood capillary → portal vein → liverLacteal → mesenteric lymph → thoracicduct → venous blood, without passingthe liver1234561LumenDietary fat is digested to fatty acids andmonoglycerides, which are solubilized with lipophiliccompounds2UptakeDigestion products and dissolved compounds crossthe apical membrane of the enterocyte3AssemblyIn the endoplasmic reticulum, triglyceride isresynthesized and MTP loads it onto apoB-48, oneper chylomicron4ExitChylomicrons (75–1,200 nm) leave across thebasolateral membrane5LactealChylomicrons are too large to cross the bloodcapillary wall and enter the more permeable lacteal,carrying highly lipophilic compounds (typically log P >5) associated with them6BloodMost absorbed molecules enter the blood capillaryand the portal vein to the liver; portal blood flow isabout 500 times intestinal lymph flowLipid uptake by an intestinal villus: digestion products and dissolved lipophilic compounds enter the enterocyte, are packed into chylomicrons on apoB-48 and leave into the lacteal, while most other absorbed molecules enter the blood capillary and the portal veinIntestinal lumenLamina propriaBlood capillary → portalvein → liverLacteal → mesentericlymph → thoracic duct →venous blood, withoutpassing the liver1234561LumenDietary fat is digested to fatty acids andmonoglycerides, which are solubilized withlipophilic compounds2UptakeDigestion products and dissolved compounds crossthe apical membrane of the enterocyte3AssemblyIn the endoplasmic reticulum, triglyceride isresynthesized and MTP loads it onto apoB-48, oneper chylomicron4ExitChylomicrons (75–1,200 nm) leave across thebasolateral membrane5LactealChylomicrons are too large to cross the bloodcapillary wall and enter the more permeable lacteal,carrying highly lipophilic compounds (typically log P> 5) associated with them6BloodMost absorbed molecules enter the blood capillaryand the portal vein to the liver; portal blood flow isabout 500 times intestinal lymph flow
Trevaskis NL, Charman WN, Porter CJH. Adv Drug Deliv Rev 2008;60:702–716, §2.1 and Fig. 1; Rahmany S, Jialal I. Biochemistry, Chylomicron. StatPearls, 2023 (apoB-48, MTP); Yáñez JA, et al. Adv Drug Deliv Rev 2011;63:923–942 (size); ICRP Publication 89, §6.3 (one lacteal per villus; lipid to the thoracic duct).
Text version of the drawing
  1. LumenFatty acid and monoglyceride digestion products are solubilized in the intestinal fluid together with lipophilic compounds.
  2. UptakeThey cross the apical membrane of the enterocytes.
  3. AssemblyIn the endoplasmic reticulum, triglyceride is resynthesized and assembled into lipoproteins; microsomal triglyceride transfer protein (MTP) lipidates apoB-48, one molecule per chylomicron.
  4. ExitChylomicrons (75–1,200 nm) are exocytosed across the basolateral membrane.
  5. LactealTheir size limits diffusion across the blood capillary wall; lymphatic capillaries are significantly more permeable, so lipoproteins and drug associated with them enter the lymph.
  6. Blood capillaryMost absorbed molecules enter the portal blood, whose flow is about 500 times that of intestinal lymph, and reach the liver first.
Factors that govern intestinal lymphatic transport and the evidence behind each
FactorWhat the reviews stateEvidence base
Lipophilicity of the compoundLymph-transported drugs are typically log P > 5Review criterion after Charman and Stella, 1986; stated as “typically”, not as a strict cutoff
Solubility in long-chain triglycerideTypically > 50 mg/gSame criterion; an exception is noted on ADME, PK and PBPK
Association with lipoproteinsThe properties of the lipoprotein, rather than the drug, dictate lymphatic accessStudies of DDT, hydrocarbons and halofantrine in lymph lipoprotein cores
Co-administered lipid: chain lengthAbout 40–60% of a dose of fatty acids with 14 or more carbons reaches the blood through the lymph; shorter, more water-soluble chains go mainly to portal bloodRat studies
Co-administered lipid: unsaturationMono- and polyunsaturated fatty acids give larger lipoproteins and more lymphatic drug transport than saturated onesMostly animal studies
Compounds recovered in lymphFat-soluble vitamins and derivatives, retinoids, lycopene, probucol, cyclosporine and others; little salicylic acid, isoniazid or caffeineMixed species; the retinoid and hydrophilic-drug data are from rats
Measurement in people“Lymphatic drug transport cannot be studied directly in humans”: lymph duct cannulation is invasiveRats, dogs, pigs, sheep and rabbits are used instead

Trevaskis NL, Charman WN, Porter CJH. Adv Drug Deliv Rev 2008;60:702–716 (§2.1–2.2, §3); Porter CJH, Trevaskis NL, Charman WN. Nat Rev Drug Discov 2007;6:231–248; Trevaskis NL, Kaminskas LM, Porter CJH. Nat Rev Drug Discov 2015;14:781–803 (lymphatic system in fluid balance, lipid metabolism and immunity; lymph-directed delivery). In greyhound dogs given testosterone undecanoate after food, 83–84% of the systemically available testosterone came from lymph-transported ester; in people, testosterone exposure after this ester rises substantially with food (Trevaskis 2008, §4).

Lymphatic transport is one reason a fat-containing meal or lipid formulation can change exposure to a very lipophilic compound. Formulation approaches are described under Bioavailability design; the gut wall and first pass under ADME, PK and PBPK.

Immune organs

In the ICRP reference man, only 0.2% of the body's lymphocytes are in the blood at any moment; other estimates put it near 2%

Lymphocytes mature in the primary lymphoid organs, bone marrow and thymus, and concentrate in the secondary ones, from which immune responses are launched: lymph nodes, spleen and lymphoid nodules. Most of the adult total of about 1.5 kg sits outside the blood-forming tissues.

Most lymphocytes live in tissues; the spleen, at 150 g, is the largest single mass of lymphatic tissueICRP Publication 89 reference values
Distribution of the body's lymphocytes and reference masses of lymphoid tissues in the ICRP Publication 89 adult male: only 0.2 percent of lymphocytes are in the bloodA Where the lymphocytes are, % (adult male)Outside hematopoietic tissuesOutside hematopoietic tissues: 85.8% of lymphocytes85.8%Red marrowRed marrow: 7% of lymphocytes7%Spleen, lymph nodes, etc.Spleen, lymph nodes, etc.: 7% of lymphocytes7%BloodBlood: 0.2% of lymphocytes0.2%B Reference mass, g (adult male, log scale)Lymphocytes, allLymphocytes, all: 1,500 g1,500Active (red) marrowActive (red) marrow: 1,170 g1,170“Fixed” lymphatic tissue“Fixed” lymphatic tissue: 730 g730SpleenSpleen: 150 g150ThymusThymus: 25 g25Mesenteric nodes, ages 20–45Mesenteric nodes, ages 20–45: 11 g11Palatine tonsils (2)Palatine tonsils (2): 3 g31101001,000Distribution of the body's lymphocytes and reference masses of lymphoid tissues in the ICRP Publication 89 adult male: only 0.2 percent of lymphocytes are in the bloodA Where the lymphocytes are, % (adult male)Outside hematopoietictissuesOutside hematopoietic tissues: 85.8% of lymphocytes85.8%Red marrowRed marrow: 7% of lymphocytes7%Spleen, lymph nodes, etc.Spleen, lymph nodes, etc.: 7% of lymphocytes7%BloodBlood: 0.2% of lymphocytes0.2%B Reference mass, g (adult male, log scale)Lymphocytes, allLymphocytes, all: 1,500 g1,500Active (red) marrowActive (red) marrow: 1,170 g1,170“Fixed” lymphatic tissue“Fixed” lymphatic tissue: 730 g730SpleenSpleen: 150 g150ThymusThymus: 25 g25Mesenteric nodes, ages20–45Mesenteric nodes, ages 20–45: 11 g11Palatine tonsils (2)Palatine tonsils (2): 3 g31101001,000
ICRP Publication 89 (2002): §7.8.2 (lymphocyte mass and distribution after Osgood 1955; “fixed” lymphatic tissue scaled from Publication 23), §7.8.1 (mesenteric nodes), Table 2.8 and §11.10–11.11 (spleen, thymus, tonsils, active marrow), adult male.
Show data: lymphocyte distribution and lymphoid masses, adult male and female
ICRP reference lymphocyte mass and distribution and lymphoid tissue masses
QuantityAdult maleAdult female
Total lymphocytes, g1,5001,300
Distribution: red marrow / blood / spleen, lymph nodes, etc. / outside hematopoietic tissues, %7.0 / 0.2 / 7.0 / 85.87.0 / 0.2 / 7.0 / 85.8
“Fixed” lymphatic tissue, g730600
Active (red) marrow, g1,170900
Spleen, g150130
Thymus, g2520
Palatine tonsils (2), g33
Mesenteric lymph nodes, g (ages 20–45)About 11
Lymphoid organs: type, structure and function
OrganTypeStructure and function
Red bone marrowPrimarySite of hematopoiesis; B cells undergo nearly all of their development here
ThymusPrimaryBilobed organ in the mediastinum where T cells from the marrow mature; 10–15 g at birth, about 30–40 g around puberty, then involution and replacement by fat
Lymph nodesSecondaryCortex, paracortex and medulla; filter lymph, and dendritic cells and macrophages remove pathogens
SpleenSecondaryThe only lymphatic organ within the bloodstream; red pulp filters blood and its macrophages recycle iron from old red cells; white pulp mounts T and B cell responses
Peyer's patches (gut-associated lymphoid tissue)Secondary, mucosa-associatedOval aggregates of 10–60 nodules, usually 1–4 cm long, mainly in the lower ileum; M (microfold) cells in the overlying epithelium take up particulate antigen; B cells there differentiate into IgA-secreting plasma cells
Tonsils and appendixSecondary, mucosa-associatedLymphoid nodules along the pharynx; aggregate nodules are always present in the appendix

OpenStax §21.1; ICRP Publication 89 (2002), §6.3 (lymphatic tissue of the gut), §7 (spleen within the bloodstream), §11.10–11.11; Panneerselvam D, Vaqar S. Peyer Patches. StatPearls, 2023; Kapila V, et al. Physiology, Spleen. StatPearls, 2023; Ozdowski L, Gupta V. StatPearls, 2023 (node structure).

Supplements A–Z entries named on this page: Vitamin K · St John's wort · Ginkgo · Ginger · Green tea · Vitamin A · Vitamin D · Iron · Copper · Zinc

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.